Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan Source: ERJ Open Res, 8 (1) 00551-2021; 10.1183/23120541.00551-2021 Year: 2022
Clinical outcomes of patients with drug-resistant and extensively drug-resistant tuberculosis in Europe Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008
South African patients with extensively drug-resistant tuberculosis have poor outcomes regardless of HIV status Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009
The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017 Year: 2017
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017
Prognosis and outcome in patients with extremely drug resistant tuberculosis from the Western Cape province, South Africa Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008
Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea Source: Eur Respir J, 54 (5) 1900811; 10.1183/13993003.00811-2019 Year: 2019
Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa Source: Annual Congress 2011 - Multidrug-resistant tuberculosis Year: 2011
Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Treatment outcomes of MDR-TB and HIV co-infection in Europe Source: Eur Respir J, 49 (6) 1602363; 10.1183/13993003.02363-2016 Year: 2017
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal Source: Eur Respir J 2013; 42: 1747-1749 Year: 2013
Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities Source: Eur Respir J, 52 (4) 1800246; 10.1183/13993003.00246-2018 Year: 2018
Death rates in patients during and after MDR-TB treatment in a semi rural area of South Africa Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
TB drug resistance in high-incidence countries Source: Eur Respir Mon 2012; 58: 95-110 Year: 2012
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021
Long-term safety and tolerability of delamanid-containing regimens in multidrug-resistant and extensively drug-resistant tuberculosis patients in a specialised treatment centre in Berlin, Germany Source: Eur Respir J, 56 (6) 2000009; 10.1183/13993003.00009-2020 Year: 2020
Clinical and mutational profile of extensively drug resistant tuberculosis cases in northern India. Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021
Treatment outcome of multi-drug resistant tuberculosis (MDR-TB) patients at a tertiary care center of Northern India. Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019